Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $42.0 million.

  • Indivior Pharmaceuticals' Net Income towards Common Stockholders rose 9090.91% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.0 million, marking a year-over-year increase of 13888.89%. This contributed to the annual value of $7.0 million for FY2024, which is 10555.56% up from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at $42.0 million for Q3 2025, which was up 9090.91% from $18.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Net Income towards Common Stockholders registered a high of $85.0 million during Q2 2023, and its lowest value of -$329.0 million during Q4 2022.
  • In the last 4 years, Indivior Pharmaceuticals' Net Income towards Common Stockholders had a median value of $45.0 million in 2025 and averaged -$5.8 million.
  • Within the past 5 years, the most significant YoY rise in Indivior Pharmaceuticals' Net Income towards Common Stockholders was 12066.87% (2023), while the steepest drop was 43880.6% (2023).
  • Over the past 4 years, Indivior Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$329.0 million in 2022, then skyrocketed by 120.67% to $68.0 million in 2023, then plummeted by 69.12% to $21.0 million in 2024, then soared by 100.0% to $42.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at $42.0 million for Q3 2025, versus $18.0 million for Q2 2025 and $48.0 million for Q1 2025.